FDA approves Pfizer’s RSV vaccine for older adults
James Spargo | June 1, 2023 | News story | Research and Development | FDA, Infections and infestations, Pfizer, RSV, Vaccine
Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 60 years or older.
Abrysvo is a bivalent RSV prefusion F (RSVpreF) vaccine which is unadjuvanted and composed of two preF proteins which have been chosen to optimise protection against RSV A and B strains.
The FDA’s decision was based on data from the global, randomised, double-blind, placebo-controlled phase 3 RENOIR (NCT05035212) trial, designed to assess the efficacy, immunogenicity and safety of a single dose of the vaccine. The trial is still ongoing, with interim results having been published in The New England Journal of Medicine.
Annaliesa Anderson PhD, senior vice president and CSO of Vaccine Research and Development at Pfizer, commented: “A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today’s approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults. Abrysvo will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available.”
Edward E Walsh MD, professor of Medicine at University of Rochester Medical Center and principal RENOIR investigator, said: “This past RSV season demonstrated the serious consequences and potential health risks this virus poses for older adults. Today’s FDA approval of Abrysvo recognises significant scientific progress and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease.”
James Spargo
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
